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BiosimilarAbstract Background: The efﬁcacy of human recombinant erythropoietins (rHuEPOs) in the treat-
ment of anemia with different etiologies is proven. Development of biosimilar rHuEPO products
with lower cost and wider availability is important for the care of anemic patients. Objective: The
aim of the present study was to determine the bioequivalence and safety of a biosimilar rHuEPO
(Pastopoitin) and compare it with the innovator product Eprex, as a standard rHuEPO.
Methods: One hundred and seven anemic patients on stable hemodialysis were recruited to this ran-
domized double-blind comparative trial and assigned to either subcutaneous Pastopoitin (n= 50) or
Eprex (n= 57). Each study group received rHuEPO at a dose of 80–120 IU/kg/week in 2–3 divided
doses for a period of 3 months. Hematologic parameters including Hemoglobin, hematocrit, RBC,
EBC, platelet, MCV, MCH and MCHC were checked every 2 weeks. Blood iron, ferritin, TIBC,
creatinine, BUN and electrolytes (Na, K, Ca and P) were evaluated monthly over the 3 months.an, P.O.
Medical
Recombinant alpha epoetin in hemodialysis patients 545Results:A signiﬁcant increase in hemoglobin, hematocrit and RBC was observed by the end of study
in both Pastopoitin and Eprex groups (p < 0.001). However, these factors were not signiﬁcantly dif-
ferent between the groups, neither at baseline nor at the end of study (p > 0.05). Likewise, the groups
were comparable regarding MCV, MCH, MCHC, iron, ferritin, TIBC, creatinine, BUN and elec-
trolytes at baseline as well as at the end of trial. Adverse events were not serious and occurred with
the same frequency in the study groups. Conclusion: Pastopoitin showed comparable efﬁcacy and
safety proﬁle with Eprex in anemic patients on hemodialysis. Hence, Pastopoitin may be considered
as a rHuEPO with a lower cost and wider availability compared with the innovator product Eprex.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anemia is a common and serious complication of chronic renal
failure (CRF) (Nurko, 2006), and is responsible for considerable
morbidity and mortality as well as severe impairment to the
quality of life in both pre-dialysis and hemodialysis patients
(Goch et al., 1992; Levin et al., 1999; Locatelli et al., 2004;
O’Riordan and Foley, 2000). Anemia in CRF patients may
either stem from defective erythropoietin production by kidneys
or iron deﬁciency, and has been reported to be correlated with
the severity of disease (Howard et al., 1989; Nurko, 2006).
Correction of anemia by increasing blood hemoglobin (Hb) or
hematocrit (Hct) values is essential for the survival of renal
transplant patients as well as for those who are on hemodialysis
(Locatelli et al., 2004; Port et al., 1998). Hence, much attempt
has been made to introduce safe and effective treatments that
can correct hematological abnormalities in anemic patients.
The major therapeutic advance for the management of ane-
mia has been the introduction of recombinant human erythro-
poietin (rHuEPO). Owing to the efﬁcacy of rHuEPO, the use
of blood transfusion or steroid therapy in CRF patients is
now obsolete. rHuEPO is indicated for both prevention and
treatment of anemia after surgery or hemodialysis (Smith
et al., 2003), and has been shown to improve the quality of life
of hemodialysis patients at both cognitive and activity levels
(Moreno et al., 2000).
Among the several types of rHuEPOs that have been pro-
duced, alpha epoetins are the most widely used class. The
innovator product of alpha epoetins is Eprex, which is a stan-
dard drug with conﬁrmed efﬁcacy and well-tolerability.
Nevertheless, alpha epoetins are not widely available and their
high cost limits their use in target patients. Since the patent of
Eprex as the proprietary drug has expired, there is a need to
develop biosimilar rHuEPO products with comparable efﬁcacy
and safety that could be used with higher availability and at a
lower cost (MacLaren and Sullivan, 2005). The present study
aimed to evaluate the efﬁcacy and safety of Pastopoitin, a
biosimilar epoetin alpha, in comparison with the innovator
product Eprex, in patients with CRF on stable hemodialysis.
2. Material and methods
The study was a randomized double-blind parallel-group trial
on patients referring to the nephrology clinics of the Madani,
Ghiyasi, Sina, Fayazbakhsh, Imam Reza and Artesh hospitals.
Inclusion criteria were male and female patients with end stage
renal disease (GFR< 14 mL/min/1.73 m2 body area) who
were receiving hemodialysis for the ﬁrst time or not longer thanthree months, hematocrit (Hct) < 30% or Hb< 10 g/dL, serum
ferritin > 100 ng/mL, iron saturation > 20% and a negative
history of erythropoietin therapy. Patients with pregnancy or
breastfeeding, CRP > 10 mg/L and a history of uncontrolled
hypertension, symptomatic ischemic heart disease, cardio-
vascular or cerebrovascular events, acute infection, elevated
hepatic transaminases, graft rejection, polycystic kidney
disease and malignancy were excluded from the trial. The
study protocol was approved by the institutional Ethics
Committee and written informed consent was obtained from
all participants.
One-hundred and seven subjects met the inclusion criteria
and were randomized to receive Pastopoitin (Pasteur
Institute; n= 50) or Eprex (Cilag Inc., Switzerland; n= 57).
Each rHuEPO product was administered at a subcutaneous
dose of 80–120 IU/kg/week, in 2–3 divided doses (after each
dialysis session) until blood Hb and Hct values reached normal
range with a maximum duration of 3 months. The values of
hematologic factors such as Hb, Hct, red blood cells (RBC),
white blood cells (WBC), platelets (PLT), mean corpuscular
volume (MCV), mean corpuscular hemoglobin (MCH), mean
corpuscular hemoglobin concentration (MCHC) and RBC dis-
tribution width (RDW) were checked every 2 weeks. Blood
iron, ferritin, total iron binding capacity (TIBC), creatinine,
blood urea nitrogen (BUN) and electrolytes (Na, K, Ca and
P) were evaluated monthly over the 3-month duration of
study. Incidence of adverse events such as headache, nausea,
vomiting, dizziness, fatigue, weakness, arthralgia, edema, chest
pain, diarrhea, rashes, myocardial infarction, transient
ischemic attack or stroke, hypertension and hypersensitivity
reactions was also recorded throughout the study.
Statistical analyses were performed using SPSS software ver-
sion 16. Data were expressed as means ± SD or number (%).
Comparisons were made using ANOVA with Bonferroni
adjustment for multiple comparisons. A two-sided p-value of
less than 0.05 was considered as signiﬁcant.3. Results
Demographic characteristics of the study groups are summar-
ized in Table 1. There was no statistically signiﬁcant difference
between the groups regarding any of the basic characteristics
including age, gender, marital status, predialysis weight, and
systolic and diastolic blood pressures (p> 0.05). Systolic and
diastolic blood pressures remained unchanged by the end of
trial (p> 0.05).
Changes in hematologic parameters during the course of
study are shown in Table 2. Mean Hb, Hct and RBC values
546 F. Beiraghdar et al.were signiﬁcantly increased by the end of trial in both groups
(p < 0.001). There was no statistically signiﬁcant difference
between the Eprex and Pastopoitin groups regarding Hb,Table 1 Demographic characteristics of the study groups.
Parameters Eprex Pastopoitin p-Value
Mean age (years) 52.51 ± 15.12 55.60 ± 14.74 0.898
Marriage statues
Single (n) 51 47 –
Marriage (n) 6 3 –
Sex (no)
Male 33 36 0.256
Female 22 17
Weight before
dialysis (kg)
64.0 ± 12.1 68.0 ± 11.2 0.147
SBP (mmHg)
Baseline 139.42 ± 21.54 141.19 ± 22.31 0.65
Endpoint 138.39 ± 20.78 139.49 ± 21.42 0.48
DBP (mmHg)
Baseline 93.27 ± 15.03 94.06 ± 12.75 0.12
Endpoint 93.22 ± 13.32 92.45 ± 13.97 0.87
SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 2 Changes in hematologic parameters in the study
groups.
Parameters Eprex Pastopoitin p-Value
Hb (g/dL)
Baseline 8.48 ± 1.14 8.47 ± 0.94 0.11
Endpoint 9.81 ± 1.21a 9.5 ± 1.25a 0.25
Hct (%)
Baseline 27.41 ± 2.96 27.44 ± 2.86 0.64
Endpoint 31.82 ± 4.19a 31.89 ± 3.11a 0.06
RBC (million/mm3)
Baseline 3.12 ± 0.45 3.13 ± 0.38 0.38
Endpoint 3.77 ± 0.68a 3.71 ± 0.43a 0.17
Platelet (1000/mL)
Baseline 197.03 ± 88.28 203.86 ± 77.9 0.53
Endpoint 186.18 ± 66.63 228.33 ± 71.78 0.18
MCV (fL)
Baseline 87.3 ± 7.41 86.61 ± 7.71 0.3
Endpoint 86.16 ± 10.61 86.98 ± 7.23 0.65
MCH (pg)
Baseline 27.16 ± 3.01 26.72 ± 2.63 0.19
Endpoint 27.76 ± 10.35 26.04 ± 2.48 0.1
MCHC (pg)
Baseline 30.83 ± 2.06 30.81 ± 1.99 0.06
Endpoint 30.70 ± 2.11 29.98 ± 1.71 0.38
WBC (103/mm3)
Baseline 6.1 ± 2.45 6.52 ± 1.84 0.23
Endpoint 5.99 ± 1.55 6.81 ± 1.72 0.45
RDW (%)
Baseline 14.39 ± 2.18 14.4 ± 1.7 0.1
Endpoint 14.03 ± 1.88 14.46 ± 1.74 0.34
Reticulocyte (%)
Baseline 1.18 ± 0.46 1.35 ± 0.67 0.04
Endpoint 1.18 ± 0.55 1.32 ± 0.61 0.37
a Signiﬁcant difference versus baseline value (p < 0.05). Hb: hemo-
globin; Hct: hematocrit; RBC: red blood cell; MCV: mean cor-
puscular volume; MCH: mean corpuscular hemoglobin; MCHC:
mean corpuscular hemoglobin concentration; WBC: white blood cell;
RDW: red blood cell distribution width.Hct, RBC, PLT, MCV, MCH, MCHC, WBC, RDW and retic-
ulocyte count, neither at baseline nor at the end of study
(p > 0.05) (Table 2).
Serum values of iron status biomarkers i.e., iron, ferritin
and TIBC, as well as biomarkers of renal function i.e., BUN
and creatinine did not signiﬁcantly change in any of the study
groups (p > 0.05). Likewise, between-group comparisons did
not reveal any difference between Pastopoitin and Eprex
groups in any of the abovementioned parameters, neither at
baseline nor at the end of study (p > 0.05) (Table 3).
Mean baseline and endpoint values for serum electrolytes
including K, Na, Ca and P in the study groups are shown in
Table 4. No signiﬁcant change in any of the electrolytes was
observed in the study groups by the end of trial. The groups
were also comparable regarding serum levels of the assessed
electrolytes at baseline and at the end of study.
Table 5 shows the frequency of adverse events reported in
the Pastopoitin and Eprex groups during the course of study.
The most common adverse events in the study groups were
weakness, arthralgia, headache and nausea. The frequency of
adverse events was not signiﬁcantly different between the study
groups (Table 5).Table 3 Changes in iron status and renal function biomarkers
in the study groups.
Parameters Eprex Pastopoitin p-Value
Iron (lg/dL)
Baseline 110.72 ± 119.11 101.73 ± 59.73 0.31
Endpoint 85.22 ± 17.7 90.66 ± 34.82 0.06
Ferritin (ng/mL)
Baseline 443.53 ± 283.61 430.66 ± 275.63 0.53
Endpoint 472.96 ± 284.54 426.61 ± 282.29 0.84
TIBC (lg/dL)
Baseline 280.69 ± 57.18 300.84 ± 75.66 0.08
Endpoint 290.04 ± 41.96 302.06 ± 74.13 0.07
BUN (mg/dL)
Baseline 63.31 ± 27.59 57.9 ± 22.8 0.16
Endpoint 65.56 ± 23.89 57.74 ± 18.52 0.9
Creatinine (mg/dL)
Baseline 9.20 ± 3.24 8.92 ± 2.79 0.4
Endpoint 10.09 ± 3.23 9.63 ± 2.93 0.95
TIBC: total iron binding capacity; BUN: blood urea nitrogen.
Table 4 Changes in serum trace element levels in the study
groups.
Parameters Eprex Pastopoitin p-Value
K (mg/dL)
Baseline 5.23 ± 1.80 5.42 ± 1.68 0.15
Endpoint 5.43 ± 0.99 5.32 ± 2.12 0.8
Na (meq/L)
Baseline 139.63 ± 3.26 138.83 ± 3.29 0.07
Endpoint 139.73 ± 2.38 139.73 ± 3.07 0.18
Ca (meq/L)
Baseline 8.59 ± 0.94 8.75 ± 0.98 0.73
Endpoint 8.66 ± 0.86 8.77 ± 1.11 0.57
P (meq/L)
Baseline 5.05 ± 1.63 5.07 ± 1.51 0.69
Endpoint 5.21 ± 1.7 5.01 ± 1.62 0.8
Table 5 Reported adverse events during the course of study.
Parameters Eprex (n) Pastopoitin (n)
Headache 13 29
Hypertension – 1
Nausea 11 6
Weakness 51 49
Arthralgia 44 23
Edema – –
Vomiting – 1
Dizziness 3 –
Fatigue 8 5
Chest Pain 5 –
Thrombosis – –
Hypersensitivity reactions – –
Rush – –
Diarrhea 2 2
MI – –
TIA/stroke – –
TIA: transient ischemic stroke.
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Effective management of anemia is integral to the care of
patients with CRF, particularly those on stable hemodialysis.
The use of rHuEpo has completely obviated the need for blood
transfusion and steroid therapy in CRF patients, thereby
reducing the adverse events commonly associated with such
conventional therapies (Locatelli et al., 2004; Schmid and
Schifﬂ, 2010; Shahani et al., 2009).
Since the pioneer trials in the 1980s, the efﬁcacy of
rHuEPOs in the management of anemia in CRF patients has
been shown by several studies. In most of the studies, subcuta-
neous injection of rHuEPO with a frequency of 2–3 times per
week has been shown to maintain Hb and Hct values within
the normal range (Biesen et al., 2005; Beiraghdar et al.,
2012a,b; Grzeszczak et al., 2005; Weiss et al., 2000). In renal
transplant patients with a Hb value of <12.5 g/dL, Biesen
et al. reported restoration of Hb following administration of
rHuEPO at a dose of 100 IU/kg, 3 times per week (Biesen
et al., 2005). In a randomized prospective trial, Van Loo
et al. showed that rHuEPO, administered at a starting subcuta-
neous dose of 150 U/kg/week followed by weekly increments
of 30 U/kg, is beneﬁcial in correcting Hct values in the early
post-surgical period in renal transplant patients (Van Loo
et al., 1996). Baltar et al. administered rHuEpo to patients with
chronic allograft nephropathy at a subcutaneous dose of
2000 IU/kg once a week. Approximately 48% of patients were
reported to reach target levels of Hb (11 g/dL) and Hct (35%)
after 4 months of treatment (Baltar et al., 2007). In the present
study, mean Hb level signiﬁcantly increased and at least 20%
of patients reached normal Hb and Hct values after 3 months
of erythropoietin therapy. Mean Hct value signiﬁcantly
increased at least 8 weeks after erythropoietin therapy, and this
was accompanied by an elevation of RBC count. These results
are consistent with previous reports (Baltar et al., 2007;
Beiraghdar et al., 2012a,b; Biesen et al., 2005; Tsiara et al.,
2007; Van Loo et al., 1996) and indicate the comparable efﬁ-
cacy of Pastopoitin with other rHuEPOs in correcting CRF-
associated anemia in hemodialysis patients. In the current
study, no signiﬁcant difference in other hematologicalparameters such as PLT, WBC and reticulocyte count as well
as MCH, MCV, MCH, MCHC, RDW, iron, TIBC and fer-
ritin was observed between the study groups. Van Loo et al.
also showed that PLT and WBC values were not signiﬁcantly
changed following rHuEPO therapy (Van Loo et al., 1996). In
the study by Baltar et al. mean serum creatinine, a determinant
of kidney function, was reported to remain constant during
treatment with rHuEPO (Baltar et al., 2007). This is consistent
with the present ﬁndings on the stable renal function during
therapy, reﬂected by the unaltered levels of creatinine and
BUN. Moreover, there was no signiﬁcant alteration in serum
electrolytes (Na and K) during the course of treatment.
Adverse effects observed in this study were generally mild
and included headache, hypertension, nausea, weakness and
arthralgia. These adverse events were not clinically serious
and their frequencies did not signiﬁcantly differ between
Pastopoitin and Eprex groups. The safety of rHuEPO has also
been shown in previous studies, as reported by Beisen et al.
(2005) and Beiraghdar et al. (2012a,b) in renal transplant
and hemodialysis patients.
The present data clearly indicate bioequivalence of the
biosimilar product Pastopoitin with the innovator product
Eprex in correcting CRF-associated anemia in hemodialysis
patients. In addition, Pastopoitin had a similar safety proﬁle
compared with Eprex. Hence, Pastopoitin may be considered
as an effective and safe biosimilar rHuEPO preparation with
a wide availability and lower cost compared to Eprex.
Future investigations are required to conﬁrm the efﬁcacy and
safety of this biosimilar alpha epoetin product in patients with
other types of anemia e.g. post-transplant patients and patients
undergoing chemotherapy.
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